SCHEMBL27101331

SCHEMBL27101331

CCCS(=O)(=O)Nc1cc(Br)cc(C(=O)Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKB Q96GD4 4/20 0.39
AURKA O14965 3/20 0.39
KDR P35968 2/20 0.39
BRD4 O60885 3/20 0.38
BRAF P15056 4/20 0.37
MAP1LC3B Q9GZQ8 1/20 0.36
ACP1 P24666 1/20 0.36
THRA P10827 1/20 0.35
PLK4 O00444 3/20 0.35
DAPK3 O43293 3/20 0.35
JAK2 O60674 3/20 0.35
CDK1 P06493 3/20 0.35
RPS6KB1 P23443 3/20 0.35
CDK2 P24941 3/20 0.35
TYK2 P29597 3/20 0.35
CLK2 P49760 3/20 0.35
JAK3 P52333 3/20 0.35
LIMK1 P53667 3/20 0.35
CDK5 Q00535 3/20 0.35
DYRK1A Q13627 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27101332 0.87 TDP1 (0.43) AURKBAURKAKDRMAP1LC3BACP1
SCHEMBL27101334 0.85 BRAF (0.42) AURKBAURKAKDRBRD4BRAF
SCHEMBL27101336 0.84 BRAF (0.41) AURKBAURKAKDRBRD4BRAF
SCHEMBL20523613 0.80 ALDH1A1 (0.41) AURKBAURKAKDRBRD4BRAF
SCHEMBL415984 0.79 MAP1LC3B (0.50) AURKBAURKAKDRBRD4MAP1LC3B
SCHEMBL9491593 0.78 HPGD (0.53) AURKBAURKAKDRBRD4THRA
SCHEMBL20523497 0.77 CYP3A4 (0.39) AURKBAURKAKDRBRD4BRAF
SCHEMBL17211757 0.76 TDP1 (0.47) AURKBAURKAKDRBRD4MAP1LC3B
SCHEMBL20523717 0.75 LMNA (0.43) AURKBAURKAKDRBRD4TP53
SCHEMBL5217087 0.74 HPGD (0.46) THRATP53HPGDMAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912701-B2 Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death HEPAREGENIX GMBH (DE) 2024-02-27 US disclosed
US-11912701-B2 Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death HEPAREGENIX GMBH (DE) 2024-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912701-B2 Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death MAPK4, MAPK7, MAPK14 AURKB 1392/4885AURKA 1658/4885KDR 2818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.